SunRegen Healthcare AG is a pioneering biopharmaceutical company based in Basel Area of Switzerland.
Our mission is to develop novel drugs inspired by traditional medicine to treat neurodegenerative diseases.
Our team is composed of passionate, innovative and persistent founders who have track records of senior drug development & clinical research in multinational pharmaceutical company or management experiences in international technology enterprises.
Neurodegenerative disorders have a high unmet medical need. Currently there are few drugs on the market which target the root cause of neurodegenerative diseases.
SunRegen has found a key active ingredient from a Chinese herb for the treatment of neurodegenerative diseases. SunRegen has established a synthetic route of compound SBC003.
The current status of the project is preclinical (in vitro and in vivo). The compound SBC003 demonstrates potent neuroprotective, anti-apoptotic, neuro-rescuing, and axon-outgrowth effects.
Swiss Commission for Technology and Innovation (CTI) offered coaching service to SunRegen Healthcare AG
SunRegen Healthcare AG fits in a drug development ecosystem including the highly acknowledged CROs, research institutions, and other drug development service organizations.
We welcome investors to join us and achieve the goals of improving our patients’ health together!
We welcome experienced scientists from CNS field or experts in preclinical up to phase II clinical development to get in contact or send your CV to email@example.com
Hot opening: Head of Preclinical Drug Development
Hot opening: Research Biochemistry Expert